Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TANIA: Bevacizumab in 2nd-line Breast Cancer
NCT01250379Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2011
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in breast cancer (2 arms), sponsored by Roche. Primary endpoints: Second-Line Progression-Free Survival at 3 years and Percentage of Participants Estimated to be Alive and Free of Second-Line Disease Progression at 24 months. Started Feb 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01250379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01250379.